Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS (GENIL) - Net Assets
Based on the latest financial reports, Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS (GENIL) has net assets worth TL9.76 Billion TRY (≈ $218.58 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (TL17.28 Billion ≈ $387.06 Million USD) and total liabilities (TL7.52 Billion ≈ $168.49 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Gen Ilac ve Saglik Urunleri Sanayi ve Ti asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | TL9.76 Billion |
| % of Total Assets | 56.47% |
| Annual Growth Rate | 100.44% |
| 5-Year Change | 1211.12% |
| 10-Year Change | N/A |
| Growth Volatility | 47.66 |
Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS - Net Assets Trend (2018–2024)
This chart illustrates how Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS's net assets have evolved over time, based on quarterly financial data. Also explore GENIL current and non-current assets for the complete picture of this company's asset base.
Annual Net Assets for Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS (2018–2024)
The table below shows the annual net assets of Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS from 2018 to 2024. For live valuation and market cap data, see market cap of Gen Ilac ve Saglik Urunleri Sanayi ve Ti.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | TL7.31 Billion ≈ $163.67 Million |
+4.17% |
| 2023-12-31 | TL7.01 Billion ≈ $157.11 Million |
+150.13% |
| 2022-12-31 | TL2.80 Billion ≈ $62.81 Million |
+118.38% |
| 2021-12-31 | TL1.28 Billion ≈ $28.76 Million |
+130.41% |
| 2020-12-31 | TL557.36 Million ≈ $12.48 Million |
+127.05% |
| 2019-12-31 | TL245.48 Million ≈ $5.50 Million |
+118.04% |
| 2018-12-31 | TL112.59 Million ≈ $2.52 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2631.1% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | TL1.72 Billion | 23.53% |
| Other Components | TL5.59 Billion | 76.47% |
| Total Equity | TL7.31 Billion | 100.00% |
Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS Competitors by Market Cap
The table below lists competitors of Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Fuxin Dare Automotive Parts Co Ltd
SHE:300473
|
$866.87 Million |
|
Goldcard High-Tech Co Ltd
SHE:300349
|
$866.93 Million |
|
Shenzhen Shengxunda Technology Co Ltd Class A
SHE:300518
|
$866.94 Million |
|
Scholastic Corporation
NASDAQ:SCHL
|
$867.31 Million |
|
IntelliEPI Cayman
TWO:4971
|
$866.72 Million |
|
Five Star Bancorp
NASDAQ:FSBC
|
$866.59 Million |
|
SHENWAN HONGYUAN GR.H YC1
F:2X2A
|
$866.52 Million |
|
Shaanxi Construction Machinery Co Ltd
SHG:600984
|
$866.38 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 6,983,908,917 to 7,306,280,022, a change of 322,371,105 (4.6%).
- Net income of 148,676,808 contributed positively to equity growth.
- Dividend payments of 333,318,003 reduced retained earnings.
- Other factors increased equity by 507,012,300.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | TL148.68 Million | +2.03% |
| Dividends Paid | TL333.32 Million | -4.56% |
| Other Changes | TL507.01 Million | +6.94% |
| Total Change | TL- | 4.62% |
Book Value vs Market Value Analysis
This analysis compares Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.35x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 23.23x to 0.35x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | TL0.37 | TL8.60 | x |
| 2019-12-31 | TL0.81 | TL8.60 | x |
| 2020-12-31 | TL1.86 | TL8.60 | x |
| 2021-12-31 | TL4.27 | TL8.60 | x |
| 2022-12-31 | TL9.31 | TL8.60 | x |
| 2023-12-31 | TL23.28 | TL8.60 | x |
| 2024-12-31 | TL24.35 | TL8.60 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.03%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1.01%
- • Asset Turnover: 1.20x
- • Equity Multiplier: 1.68x
- Recent ROE (2.03%) is below the historical average (25.05%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 5.30% | 0.50% | 2.86x | 3.72x | TL-5.22 Million |
| 2019 | 58.30% | 7.91% | 3.20x | 2.30x | TL117.59 Million |
| 2020 | 37.39% | 9.69% | 1.99x | 1.94x | TL152.54 Million |
| 2021 | 24.26% | 12.43% | 1.18x | 1.65x | TL182.71 Million |
| 2022 | 38.67% | 19.84% | 1.48x | 1.32x | TL801.07 Million |
| 2023 | 9.40% | 5.58% | 1.06x | 1.59x | TL-42.07 Million |
| 2024 | 2.03% | 1.01% | 1.20x | 1.68x | TL-581.95 Million |
Industry Comparison
This section compares Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $1,337,831,136
- Average return on equity (ROE) among peers: 17.63%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS (GENIL) | TL9.76 Billion | 5.30% | 0.77x | $866.78 Million |
| Deva Holding AS (DEVA) | $1.03 Billion | 27.75% | 1.06x | $322.33 Million |
| EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS (ECILC) | $2.92 Billion | 2.10% | 0.18x | $1.40 Billion |
| Turk Ilac ve Serum Sanayi AS (TRILC) | $62.47 Million | 23.04% | 2.04x | $13.81 Million |
About Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS
Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi, a pharmaceutical company, manufactures and supplies products to treat rare diseases and disorders worldwide. The company offers its products in various areas, such as neurology, endocrinology, nephrology, oncology, hematology, and pediatric. Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi has collaboration with Sulfateq BV… Read more